Patient-derived neuronal models for pharmacogenetic pain treatment of sodium channelopathies

Propositions belonging to the thesis

“Patient-derived neuronal models for pharmacogenetic pain treatment of sodium channelopathies”

JULIE I.R. LABAU
MAASTRICHT, APRIL 21st, 2022

---

1. *In vitro* electrophysiology should be used to predict lacosamide responsiveness in patients carrying *SCN9A* mutations (*this thesis*)

2. Channeling the inner pore: For the first time, the voltage-sensing domain plays a role in the binding of an anti-epilectic drug (*this thesis*)

3. Recovering patient-derived native cell qualities is critical to optimizing translational pain studies (*this thesis*)

4. Dynamic clamp allows for the functional expression of all three main painful sodium channels in stem cells (*this thesis*)

5. The incorporation of routine pharmacogenomic testing in chronic pain patients will significantly improve treatment outcomes (*valorisation*)

6. Personalized medicine will be a prelude to the end of the opioid crisis.

7. Electricity is in the air, sodium channels become Big Pharma targets

8. Back to the source: Scientists are exploring 'new' ways to treat pain, deriving drugs from plants and venomous animals

9. A life without pain is a short-lived one

10. "Quand tu crois enfin que tu t'en sors, quand il n'y en a plus, il y en a encore" - Stromae

11. "Everything is theoretically impossible, until it's done" - Robert A. Heinlein

12. "Every mountain top is within reach if you just keep climbing" - Barry Finlay